Safety of Monoclonal Antibodies in Myeloma

Feb 1, 2017

Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.

While infusion reactions can occur, pre-medication is recommended. Also, reactions do not usually persist past the first infusion. For daratumumab, these reactions can also affect the upper respiratory system. Also in daratumumab, the agent can affect red cell cross-matching for transfusion. Therefore, all cross-matching should take place before infusions.

To learn more about these treatments, watch Monoclonal Antibodies in Multiple Myeloma.

Ropeginterferon Alfa-2b Listed in NCCN Guidelines as A Preferred Polycythemia Vera Treatment

May 29th 2023

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

April 13th 2023

Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries

May 25th 2023

Oncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic Leukemia

March 15th 2023

Venetoclax/Obinutuzumab–Based Combinations Improve Undetectable MRD Rates in Fit Patients With CLL

May 23rd 2023

FDA Greenlights Avapritinib for Indolent Systemic Mastocytosis

May 22nd 2023

Ropeginterferon Alfa-2b Listed in NCCN Guidelines as A Preferred Polycythemia Vera Treatment

May 29th 2023

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

April 13th 2023

Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries

May 25th 2023

Oncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic Leukemia

March 15th 2023

Venetoclax/Obinutuzumab–Based Combinations Improve Undetectable MRD Rates in Fit Patients With CLL

May 23rd 2023

FDA Greenlights Avapritinib for Indolent Systemic Mastocytosis

May 22nd 2023

Ropeginterferon Alfa-2b Listed in NCCN Guidelines as A Preferred Polycythemia Vera Treatment

May 29th 2023

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

April 13th 2023

Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries

May 25th 2023

Oncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic Leukemia

March 15th 2023

Venetoclax/Obinutuzumab–Based Combinations Improve Undetectable MRD Rates in Fit Patients With CLL

May 23rd 2023

FDA Greenlights Avapritinib for Indolent Systemic Mastocytosis

May 22nd 2023

Related Content

Ropeginterferon Alfa-2b Listed in NCCN Guidelines as A Preferred Polycythemia Vera Treatment

May 29th 2023

Article

Updated National Comprehensive Cancer Network guidelines recommend ropeginterferon alfa-2b for patients with polycythemia vera.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

April 13th 2023

Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries

May 25th 2023

Article

Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.

Oncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic Leukemia

March 15th 2023

Podcast

In this episode of The Vitals, Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses the treatment journey of a patient who required multiple lines of therapy for ALL.